An observational study in Burns, sponsored by Saint-Louis Hospital, Paris, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-07.
Sponsored by Saint-Louis Hospital, Paris, France · Observational
Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.
Among the 32 studies in Burns with a site in France, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2017, is one of 10 observational ones, and was the 20th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
CUTISS AG · Sites in France, Belgium, Germany and 6 more countries
Ages 12+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 84 Burns studies recruiting now, 38 (45%) set no upper age limit and 37 (44%) stop at 75 or younger; 17 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 64 across 163 observational studies indexed under Burns.
Median enrollment 27 across the 22 interventional studies, 72 across the 10 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
Saint-Louis Hospital, Paris, France is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Saint-Louis Hospital, Paris, France has 2 studies filed under Burns — fewer than ten, so there is no comparison to draw.
4 of the studies in Burns with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06745557Phase 3CUTISS AGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | 2027-06-30 |
| NCT06487910Centre Hospitalier Régional Metz-ThionvilleDifferential Pressure Distribution Orthosis by 3D Printing Process in the Treatment of Post-burn Hypertrophic Scarring | 2027-01-10 |
| NCT04264065Assistance Publique - Hôpitaux de ParisAlbumin and Prognosis of Severely Patients Burns | 2027-01-16 |
| NCT06469970Centre Hospitalier Régional Metz-ThionvilleEvolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults | 2027-03-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Burns with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Burn injury leads to hypovolemic then distributive shock. Fluid resuscitation remains the cornerstone of initial treatment of burn shock. However, fluid rescucitation can lead to fluid overload, which manifests most notably as lung edema.
The peptide NT-pro-BNP, a biomarker of cardiac congestion secreted by the myocardium, as well as plasma CD146, an endothelial factor involved in angiogenesis and a marker of vascular congestion, may help identifying patients with risk of pulmonary edema and hypoxia .
Our hypothesis is that these biomarkers may predict the occurence of pulmonary edema in severe burns patients.
Severely ill burn patients admitted to a tertiary referral burn center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lung edema
Extravascular lung water (EVLW) \> 10 mL/Kg as measured by transpulmonary thermodilution (TPTD)
Time frame: During the first 7 days of admission
Hypoxemia
PaO2/FiO2 ratio of \<200
Time frame: During the first 7 days of admission for mechanically-ventilated patients
Hypercapnia
PaCO2\> 45 mmHg
Time frame: During the first 7 days of admission for mechanically-ventilated patients
Corrected minute ventilation > 10L/min
Minute ventilation × partial \[Paco2\]/40) \> 10L/min
Time frame: During the first 7 days of admission for mechanically-ventilated patients
Multiple organ dysfunction syndrome (MODS)
Sequential Organ Failure Assessment score (SOFA) ≥ 8
Time frame: During the first 7 days of admission
28-day mortality
Time frame: 28 days
90-day mortality
Time frame: 90 days
Length of stay in the ICU
Time frame: until 90 days of hospitalization
Plan to share: No
Started Aug 2017 (actual). Primary completion is estimated for Feb 2019, 18 months after the start.
Of 56 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 18 months is below that.
Counting every sponsor, half of 68 studies reached it within 24 months; a quarter within 14 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint-Louis Hospital, Paris, France